NeuroprotectionResearch Market

NA-Selank Amidate

An N-acetylated, amidated form of Selank designed for enhanced stability and nasal bioavailability, studied for anxiolytic and nootropic effects via tuftsin-related immune modulation.

AnxietyNootropicImmuneSelank

Also referenced as: N-Acetyl Selank Amidate, NASA

Also appears in: Immune

Price compare
27 tracked offers across 27 vendors · 13 dosages
Best trust-adjusted value: Peptuvia · Strong trust · $1.12/mg
From
$1.12/mg
Tracked market history

What has the price actually done?

Daily, exact-comparability offers. Discounts use the terms known on each historical date.

-37.1%vs. Aug 10
Current low$1.12/mg
Market median$3.33/mg
Current coverage9 vendors
Observed window90 daily points
Lowest effective priceMarket median
Compare current offers
How this history is calculated

Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when N-Acetyl Selank Amidate crosses your target, drops, or sets a new tracked low—without daily noise.

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.
Public product evidence33 certificate records mentioning this compound or product name8 provider-linked · 30 exact product matches
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Neuroprotection

Primary research area: Neuroprotection. Also surfaces under Immune for browsing and discovery.

Aliases
2

N-Acetyl Selank Amidate, NASA

Signal depth
Medium

No FDA label signal · 462 trials · 15961 PubMed results

Promising
Research evidence

NA-Selank Amidate has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

NA-Selank Amidate has 2 name-matched clinical trials (highest phase: Phase 2) and 15961 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 2
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
PHASE2 · RandomizedNeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) MelanomaNA · RandomizedEffects of Flow Magnitude on Cardiorespiratory Stability During Nasal High Flow Therapy in Preterm InfantsAdvances in psychology · 14,734 citationsDevelopment of NASA-TLX (Task Load Index): Results of Empirical and Theoretical ResearchProceedings of the Human Factors and Ergonomics Society Annual Meeting · 4,243 citationsNasa-Task Load Index (NASA-TLX); 20 Years LaterAtmospheric chemistry and physics · 2,175 citationsAsian emissions in 2006 for the NASA INTEX-B missionJournal ArticlePerceived Nursing Interruptions During Medication Administration: Development and Validation of a Questionnaire Among Chinese Nurses.
Evidence history
  1. 2026-09-04Preclinical→PromisingBand Preclinical → Promising; +9 trials; +4 PubMed
  2. 2026-09-03Promising→PreclinicalBand Promising → Preclinical; -4 trials; +13 PubMed
  3. 2026-09-01Preclinical→PromisingBand Preclinical → Promising; +4 trials
  4. 2026-08-28Promising→PreclinicalBand Promising → Preclinical; -13 trials; +7 PubMed
  5. 2026-08-22Preclinical→PromisingBand Preclinical → Promising; +9 trials; +2 PubMed
  6. 2026-08-20Early→PreclinicalBand Early → Preclinical; -4 trials; +1 PubMed
  7. 2026-08-19Preclinical→EarlyBand Preclinical → Early; -5 trials; +4 PubMed
  8. 2026-08-18Promising→PreclinicalBand Promising → Preclinical; +5 trials; +1 PubMed
  9. 2026-08-15Early→PromisingBand Early → Promising; -18 trials; +5 PubMed
  10. 2026-08-14Preclinical→EarlyBand Preclinical → Early; +18 trials; +5 PubMed
  11. 2026-08-13Promising→PreclinicalBand Promising → Preclinical; +4 trials; +3 PubMed
  12. 2026-08-05Preclinical→PromisingBand Preclinical → Promising; -22 trials; +4 PubMed
  13. 2026-07-31Promising→PreclinicalBand Promising → Preclinical; -4 trials; +4 PubMed
  14. 2026-07-30Preclinical→PromisingBand Preclinical → Promising; +4 trials; +1 PubMed
  15. 2026-07-28Promising→PreclinicalBand Promising → Preclinical; +5 trials; +3 PubMed
  16. 2026-07-25Preclinical→PromisingBand Preclinical → Promising; +9 trials; +1 PubMed

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What is NA-Selank Amidate?

NA-Selank Amidate is a modified version of Selank, a synthetic heptapeptide analog of tuftsin (the naturally occurring immunomodulatory peptide fragment of IgG). The modifications — N-acetylation at the N-terminus and amidation at the C-terminus — are designed to improve resistance to enzymatic degradation and extend the peptide’s biological half-life compared to unmodified Selank.

How it works

The core mechanism is shared with Selank:

  • Tuftsin pathway — Selank is a synthetic extension of tuftsin (Thr-Lys-Pro-Arg), a tetrapeptide released from the Fc domain of IgG during phagocytosis. Tuftsin stimulates phagocytic activity of monocytes and neutrophils (Nishioka, Molecular and Cellular Biochemistry, 1979)
  • GABA modulation — Selank has been shown to modulate GABA-A receptor sensitivity and influence BDNF expression in the hippocampus (Semenova et al., Doklady Biological Sciences, 2010)
  • Anxiolytic effects — In preclinical models, Selank showed anxiolytic activity comparable to benzodiazepines without sedation or dependence (Seredenin et al., Bulletin of Experimental Biology and Medicine, 1998)
  • Enhanced stability — the N-acetyl and amide modifications reduce aminopeptidase and carboxypeptidase degradation, extending the effective duration per administration

Research status

Selank (the parent peptide) has more clinical data than most research peptides, though primarily in Russian literature:

  • Zozulya et al. (2008) reviewed the anxiolytic and nootropic properties of Selank in clinical and preclinical settings (Zhurnal Nevrologii i Psikhiatrii, 108(4):50–57)
  • Seredenin et al. (1998) demonstrated anxiolytic effects of Selank in elevated plus-maze and conflict tests (Bulletin of Experimental Biology and Medicine, 126(4):1079–1082)
  • Selank is approved in Russia as an intranasal anxiolytic (registration: PN002160)

The specific NA-Amidate modification has not been studied in published clinical trials — it is a vendor-driven formulation designed for improved stability.

Key considerations

  • Selank (the parent compound) has Russian regulatory approval, which is unusual for research peptides
  • The NA-Amidate form is not the version studied in clinical trials — it is a stability modification for the research market
  • Typically administered intranasally from research vendors (spray formulations)
  • Often stacked with NA-Semax Amidate, the analogous modified form of the nootropic peptide Semax